Illinois Municipal Retirement Fund Has $19.72 Million Holdings in Boston Scientific Corporation $BSX

Illinois Municipal Retirement Fund decreased its position in Boston Scientific Corporation (NYSE:BSX) by 15.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 183,623 shares of the medical equipment provider’s stock after selling 33,535 shares during the period. Illinois Municipal Retirement Fund’s holdings in Boston Scientific were worth $19,723,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of BSX. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC bought a new position in shares of Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Boston Scientific by 72.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 145 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 175,782 shares of company stock valued at $17,742,314 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.0%

NYSE:BSX opened at $100.05 on Monday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average is $100.09 and its 200 day moving average is $102.53. The stock has a market capitalization of $148.32 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the business posted $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Barclays increased their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. UBS Group upped their target price on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Truist Financial boosted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.